BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 28534291)

  • 1. Ultra-Sensitive Measurement of IL-17A and IL-17F in Psoriasis Patient Serum and Skin.
    Soderstrom C; Berstein G; Zhang W; Valdez H; Fitz L; Kuhn M; Fraser S
    AAPS J; 2017 Jul; 19(4):1218-1222. PubMed ID: 28534291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis.
    Kolbinger F; Loesche C; Valentin MA; Jiang X; Cheng Y; Jarvis P; Peters T; Calonder C; Bruin G; Polus F; Aigner B; Lee DM; Bodenlenz M; Sinner F; Pieber TR; Patel DD
    J Allergy Clin Immunol; 2017 Mar; 139(3):923-932.e8. PubMed ID: 27502297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin.
    Johansen C; Usher PA; Kjellerup RB; Lundsgaard D; Iversen L; Kragballe K
    Br J Dermatol; 2009 Feb; 160(2):319-24. PubMed ID: 19016708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of genetic polymorphism of interleukin-17A & interleukin-17F with susceptibility of psoriasis.
    Kaur R; Rawat AK; Kumar S; Aadil W; Akhtar T; Narang T; Chopra D
    Indian J Med Res; 2018 Oct; 148(4):422-426. PubMed ID: 30666004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-17A, IL-22, IL-6, and IL-21 Serum Levels in Plaque-Type Psoriasis in Brazilian Patients.
    de Oliveira PS; Cardoso PR; Lima EV; Pereira MC; Duarte AL; Pitta Ida R; Rêgo MJ; Pitta MG
    Mediators Inflamm; 2015; 2015():819149. PubMed ID: 26351408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-17 in cutaneous lupus erythematosus.
    Tanasescu C; Balanescu E; Balanescu P; Olteanu R; Badea C; Grancea C; Vagu C; Bleotu C; Ardeleanu C; Georgescu A
    Eur J Intern Med; 2010 Jun; 21(3):202-7. PubMed ID: 20493423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.
    Glatt S; Baeten D; Baker T; Griffiths M; Ionescu L; Lawson ADG; Maroof A; Oliver R; Popa S; Strimenopoulou F; Vajjah P; Watling MIL; Yeremenko N; Miossec P; Shaw S
    Ann Rheum Dis; 2018 Apr; 77(4):523-532. PubMed ID: 29275332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of IL-17F via the induction of IL-6 in psoriasis.
    Fujishima S; Watanabe H; Kawaguchi M; Suzuki T; Matsukura S; Homma T; Howell BG; Hizawa N; Mitsuya T; Huang SK; Iijima M
    Arch Dermatol Res; 2010 Sep; 302(7):499-505. PubMed ID: 20148256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of Th17 cells in patients with relapsing-remitting multiple sclerosis: interleukin-17A and interleukin-17F serum levels.
    Babaloo Z; Aliparasti MR; Babaiea F; Almasi S; Baradaran B; Farhoudi M
    Immunol Lett; 2015 Apr; 164(2):76-80. PubMed ID: 25625963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-17A biomarker as a predictor for detection of early axial spondyloarthritis changes in patients with psoriasis.
    Saif DS; El Tabl MA; Afifi N; Abdallah MS; El Hefnawy SM; Hassanein SA
    Int J Rheum Dis; 2020 Dec; 23(12):1664-1669. PubMed ID: 33016599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum concentration of osteopontin and interleukin 17 in psoriatic patients.
    Przepiórka-Kosińska JM; Bartosińska J; Raczkiewicz D; Bojar I; Kosiński J; Krasowska D; Chodorowska G
    Adv Clin Exp Med; 2020 Feb; 29(2):203-208. PubMed ID: 32109010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlations between concentrations of interleukin (IL)-17A, IL-17B and IL-17F, and endothelial cells and proangiogenic cytokines in systemic lupus erythematosus patients.
    Robak E; Kulczycka-Siennicka L; Gerlicz Z; Kierstan M; Korycka-Wolowiec A; Sysa-Jedrzejowska A
    Eur Cytokine Netw; 2013 Mar; 24(1):60-8. PubMed ID: 23661335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-17FT7488 allele is associated with a decreased risk of colorectal cancer and tumor progression.
    Nemati K; Golmoghaddam H; Hosseini SV; Ghaderi A; Doroudchi M
    Gene; 2015 Apr; 561(1):88-94. PubMed ID: 25680555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional characterization of IL-17F as a selective neutrophil attractant in psoriasis.
    Watanabe H; Kawaguchi M; Fujishima S; Ogura M; Matsukura S; Takeuchi H; Ohba M; Sueki H; Kokubu F; Hizawa N; Adachi M; Huang SK; Iijima M
    J Invest Dermatol; 2009 Mar; 129(3):650-6. PubMed ID: 18830271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Genetic Variants of the Interleukin-17F rs763780 and its Circulating Level in Psoriasis Patients in Egypt.
    Fouad NA; Akl EM; Ahmed SH
    Egypt J Immunol; 2020 Jun; 27(2):39-46. PubMed ID: 33548976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased IL-17A/IL-17F expression ratio represents the key mucosal T helper/regulatory cell-related gene signature paralleling disease activity in ulcerative colitis.
    Iboshi Y; Nakamura K; Fukaura K; Iwasa T; Ogino H; Sumida Y; Ihara E; Akiho H; Harada N; Nakamuta M
    J Gastroenterol; 2017 Mar; 52(3):315-326. PubMed ID: 27178567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signalling of multiple interleukin (IL)-17 family cytokines via IL-17 receptor A drives psoriasis-related inflammatory pathways.
    Tollenaere MAX; Hebsgaard J; Ewald DA; Lovato P; Garcet S; Li X; Pilger SD; Tiirikainen ML; Bertelsen M; Krueger JG; Norsgaard H
    Br J Dermatol; 2021 Sep; 185(3):585-594. PubMed ID: 33792895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating T-helper 17 cells and associated cytokines in psoriasis.
    Chhabra S; Narang T; Joshi N; Goel S; Sawatkar G; Saikia B; Dogra S; Bansal F; Minz R
    Clin Exp Dermatol; 2016 Oct; 41(7):806-10. PubMed ID: 27480070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of the miRNA-155, miRNA-210, and miRNA-20b in psoriasis patients and their relation to IL-17.
    El-Komy M; Amin I; El-Hawary MS; Saadi D; Shaker O
    Int J Immunopathol Pharmacol; 2020; 34():2058738420933742. PubMed ID: 32602388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis.
    Reis J; Vender R; Torres T
    BioDrugs; 2019 Aug; 33(4):391-399. PubMed ID: 31172372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.